Utilizing 'omics tools to investigate the impact of process changes on product quality in cell culture-based influenza vaccine production

摘要

The platform of pyrosequencing, glycoanalysis and immunogenicity assays allows to investigate immunogenic differences of influenza virus glycovariants. Hemagglutinin N-glycosylation has a significant impact on immunogenicity. The differential immune stimulatory effects mediated by the influenza virus glycovariants seem to be also relevant in vivo. These findings might impact cell line-based influenza vaccine design.